Stem Cell Therapy for Bone Fracture Non-Union

What This Article Covers

This article looks at stem cell and bone-marrow-derived cell therapy for fracture non-union — bone breaks that have failed to heal on their own months after injury, often despite surgery, bone grafts, or bone stimulators. It explains how the treatment is thought to work, summarizes what real clinical studies have found, describes who is typically considered for it, and is honest about where evidence is strong, where it's limited, and what the FDA says about approval status. For patients facing repeat operations, stem cell and bone marrow cell injections have become one of the more actively studied "biologic" add-on treatments in orthopedic trauma care.

How It's Thought to Work

Bone naturally heals through a coordinated process involving mesenchymal stem cells (MSCs) — cells capable of turning into bone-forming osteoblasts — along with growth factors and blood supply to the fracture site. In a non-union, that process stalls, sometimes because too few progenitor cells reach the site, blood supply is poor, or the fracture gap is unstable.

The therapy typically involves harvesting a patient's own bone marrow, most often from the iliac crest (hip bone), then concentrating it (bone marrow aspirate concentrate, or BMAC) or, less commonly, culture-expanding the MSCs before injecting them percutaneously into the fracture site — delivering a higher concentration of bone-forming progenitor cells where healing has stalled, sometimes alongside a scaffold material such as hydroxyapatite or collagen.

What the Evidence Shows

The evidence here is more developed than for many regenerative medicine applications, though it remains far from conclusive. A 2025 systematic review and meta-analysis in BMC Musculoskeletal Disorders pooled 21 studies covering 866 patients treated with MSC therapy for non-union fractures. The results were genuinely encouraging: healing rates climbed from 44% at 3 months to 73% at 6 months and 90% at 9 months, settling around 91% beyond 12 months of follow-up. Compared with standard care (typically autologous bone grafting), MSC therapy was linked to higher odds of healing at the 3- and 6-month marks, and — notably — a lower complication rate overall (about 1% versus 8% for standard care). The authors called MSC therapy "a potential adjunct therapy" for non-union fractures — a measured but genuinely hopeful conclusion.

Earlier case-series data add texture to this picture. A 2021 review in Trauma summarizing the human literature points to pioneering work by Hernigou and colleagues using percutaneous bone marrow grafting, in which the large majority of treated tibial non-unions went on to unite. That same review was candid about limitations, though: despite data going back decades, it found no Level I or Level II (high-quality randomized) evidence, and noted many trials registered on ClinicalTrials.gov had never published results. A separate 2023 systematic review reached a similar conclusion — outcomes across small case series were generally positive, but studies varied widely in cell preparation and dosing.

Across these sources, the pattern is consistent: multiple independent research groups report favorable union rates and a good safety profile, a genuinely positive signal for a hard-to-treat condition. Still, most studies are small, uncontrolled case series rather than large randomized trials, so the true added benefit over standard bone grafting is still being worked out.

Who Might Be a Candidate

• Patients with a radiographically confirmed fracture non-union or delayed union, typically 6-9+ months post-injury with no healing progress
• Those who have already tried, or are poor candidates for, revision surgery, autologous bone grafting, or bone growth stimulators
• Patients with atrophic ("biologically quiet") non-unions, where a lack of healing cells or blood supply is a major suspected factor
• Individuals enrolled in, or seeking access to, a registered clinical trial studying bone marrow concentrate or MSC therapy for non-union
• Patients without active infection at the fracture site or other conditions known to impair bone healing, common screening criteria in published studies
• Not appropriate as a first-line or stand-alone treatment outside of a clinical trial or specialized center given the current evidence

Bottom Line

Stem cell and bone marrow cell therapy for fracture non-union is one of the more evidence-backed applications in regenerative orthopedics, with real human data — including a 2025 meta-analysis of over 850 patients — showing high eventual union rates and a favorable complication profile versus standard bone grafting. That said, this therapy is not FDA-approved for fractures or any orthopedic condition in the U.S. outside a registered clinical trial, and the FDA has warned that unapproved regenerative products marketed by clinics can carry serious risks, including infection and tumor growth. Most supporting studies remain small case series rather than large randomized trials, so patients considering this option should talk with an orthopedic specialist, ask about clinical trial enrollment, and treat any marketing claim of guaranteed healing with skepticism.